OBJECTIVES: Recent studies suggest hypogammaglobulinemia (HGG) is frequently associated with infection after solid organ transplantation, although the effects of HGG after lung transplantation are not well recognized. We investigated the incidence and degree of HGG after lung transplantation and its association with infection.
INTRODUCTION
Lung transplantation is the last established therapeutic option for patients with end-stage respiratory failure. Despite improvements in immunosuppression and antimicrobial prophylaxis, infections remain a major source of morbidity and mortality among solid organ transplant recipients. Lung transplantation has poor outcomes relative to transplantations of other organs, probably because of the higher levels of immunosuppression and exposure of the lung allograft to the ambient non-sterile environment [1] . Therefore, optimal immune monitoring has been sought. The role of cellular immune monitoring in predicting infection after liver transplant has previously been demonstrated [2] , and monitoring of humoral immunity by measurement of immunoglobulin (Ig) levels at baseline and during the post-transplant period may also be useful in predicting clinical outcomes in liver [3, 4] , kidney [5] and heart transplantation [6] . Four studies have assessed hypogammaglobulinemia (HGG) after lung transplant in adults [1, [7] [8] [9] , but only one of them has compared pre-and post-transplant Ig levels in detail [1] .
Here, we review our single-institution experience with lung transplantation and assess the relationship between HGG and the incidence of post-transplant infection and survival.
PATIENTS AND METHODS
The study was approved by the institutional review board at Kyoto University. We collected demographic, clinical and laboratory data from the electronic medical records and performed a retrospective cohort study of patients undergoing lung transplantation at Kyoto University Hospital between June 2008 and March 2013. During this period, 35 cases of living-donor lobar lung transplantation (LDLLT) and 24 cases of cadaveric lung transplantation (CLT) were recorded. Cases involving patients under 10 years of age and those lacking data on Ig levels before and 3 months after lung transplant were excluded. In 3 patients who had received periodic intravenous immunoglobulin (IVIG) after haematopoietic stem cell transplantation (HSCT), Ig levels recorded just before IVIG therapy were used in the analysis. Finally, 16 cases of LDLLT and 13 cases of CLT were included. All patients were routinely followed by the lung transplant team in our department and by their own neighbourhood medical providers.
All patients received a combination of a calcineurin inhibitor (tacrolimus or cyclosporine), antimetabolite [mycophenolate mofetil (MMF) or azathioprine] and prednisone for maintenance immunosuppressive therapy. Target trough levels for tacrolimus and cyclosporine were 10-20 and 250-350 ng/ml during the first 3 months, 10-15 and 200-300 ng/ml during the following 3-6 months and 8-12 and 150-250 ng/ml thereafter, respectively. After transplantation, MMF or azathioprine was administered at 1000-2000 mg/day or 2 mg/kg/day. MMF was substituted for azathioprine when acute rejection occurred, and azathioprine was substituted for MMF when infection occurred. Prednisone was tapered to 0.4 mg/kg/day at 6 months postoperatively. Induction therapy was not used in our institution. Initial broad-spectrum antibiotic coverage was rapidly tapered to culture-specific coverage or discontinued within 1 week. Cytomegalovirus (CMV) prophylaxis consisted of i.v. ganciclovir from 1 to 4 weeks after transplant, oral valganciclovir from 1 to 3 months after transplant and oral aciclovir after 3 months with monitoring of blood CMV levels by polymerase chain reaction. Prophylaxis against Pneumocystis carinii consisted of trimethoprim-sulphamethoxazole administration three times weekly. Acute rejection was diagnosed only on the basis of radiographic and clinical findings. Trans-bronchial biopsy was avoided in LDLLT patients in order to avoid unexpected intragraft bleeding. Acute rejection was treated with a bolus dose of 10 mg/kg methylprednisolone daily for 3 days.
Pre-and post-transplant immunoglobulin levels
We retrospectively compared pre-and post-lung transplant IgA, IgG and IgM levels. The post-transplant Ig levels were obtained at 3 months post-transplant during a stable phase without infection or rejection. Although there were relatively few lung transplants overall, we also investigated Ig levels in each underlying lung disease.
Comparisons among underlying diseases
We analysed the differences in pre-and post-transplant Ig levels associated with the underlying diseases, including bronchiolitis obliterans (BO) after HSCT, interstitial lung diseases (ILDs), bronchiectasis (BE), emphysema, cystic fibrosis and BO after LDLLT. Results for the diseases that affected >5 patients, which were BO after HSCT, ILDs and BE, were included in the analysis.
Post-transplant HGG and infection events
IgG levels >700 mg/dl indicated normal gammaglobulinemia (NGG) and those <700 mg/dl indicated HGG. We compared the prevalence and incidence of infection and survival between NGG and HGG patients. In addition, we compared the incidence of infection and survival between non-severe HGG (IgG levels >400 mg/dl) and severe HGG (IgG levels < 400 mg/dl).
Statistical analysis
All statistical analyses were performed using STATVIEW v5.0 (Abacus Concepts, Inc., Berkeley, CA, USA). Values are expressed as means ± standard deviation. We used Student's paired t-tests to explore differences between pre-and post-transplant IgA, IgG and IgM levels in each group and one-way analysis of variance (ANOVA) and Scheffe's post hoc multiple comparison test to explore the differences among underlying diseases. The infection rates and survival rates were expressed as the population proportion and its confidence interval and compared between the groups with χ 2 test. Significance was defined as P < 0.05.
RESULTS
The baseline characteristics of the patients are described in Table 1 . The mean follow-up period was 20.5 ± 13.5 months (median, 19.3 months). Three of the 29 patients died, and the overall survival was 89.7%. Three dead recipients were transplanted for BO after HSCT and had HGG after transplant; 1 patient had aspergillus infection at the bronchial anastomosis and the lung, later died of chronic lung allograft dysfunction on post-transplant day (PTD) 513; another with quite low HGG died of severe pneumonia on PTD 268; the other with severe HGG suffered severe pneumonia, later died of post-transplant lymphoproliferative disorder on PTD 159.
Pre-and post-transplant immunoglobulin levels
Paired Ig levels before and after transplantation were available in 29 cases. As a whole, IgA, IgG and IgM levels significantly decreased after transplant (P < 0.0001, P < 0.0001, P = 0.011, respectively; Fig. 1 , Table 2 ). Among 11 patients transplanted for BO after HSCT, 8 (72.7%) had received immunosuppressant drugs preoperatively. Post-transplant IgA and IgG levels in the patients transplanted for BO after HSCT were significantly lower than the pretransplant levels (P = 0.0043, P = 0.0118; Fig. 2A , Table 2 ). Five of the 10 ILDs patients (50%) received immunosuppressant drugs preoperatively, and posttransplant IgA and IgG levels in the ILDs patients were significantly lower than the pretransplant levels (P = 0.0009, P = 0.0003; Fig. 2B , Table 2 ). While only 5 patients underwent transplantation for BE, the post-transplant IgA and IgG levels were still significantly lower than the pretransplant levels (P = 0.0061, P = 0.0076; Fig. 2C , Table 2 ). Pre-and post-transplant IgM levels did not show significant differences in each underlying disease (Table 2) .
Immunoglobulin comparisons among underlying diseases
Pretransplant IgA levels were significantly lower in BO after HSCT patients than in those with ILDs and BE, and the differences in post-transplant IgA levels were also significant. Pretransplant IgG levels were normal in 24 patients (82.8%) and <700 mg/dl in 5 patients (17.2%), whose respective underlying diseases were BO after HSCT (n = 3), ILD (n = 1) and emphysema (n = 1). Pretransplant
IgG levels were significantly lower in BO after HSCT patients than in those with ILDs and BE. Post-transplant IgG levels in BO after HSCT patients were also lower than those in the others, but not significantly, as was the finding for pre-and post-transplant IgM changes among the underlying diseases (Fig. 3 ).
Hypogammaglobulinemia and post-transplant infection
Nineteen of the 29 patients had HGG after lung transplantation (65.5%) ( Table 3 ). Ten of the 11 patients transplanted for BO after HSCT had HGG, while most patients transplanted for ILDs and BE maintained NGG. Data are shown as mean ± SD and P-values are reported for the differences between pre-and post-transplant Ig levels by Student's paired t-tests.
HSCT: haematopoietic stem cell transplantation. Patients in both groups had CMV antigenaemia and 2 patients in the HGG group had CMV colitis. No patient in the NGG group had CMV infection. Three patients in each group had bacterial pneumonia and all recovered. One patient in the HGG group had chlamydial pneumonia and also recovered quickly. One patient in each group had bronchial aspergillus infection and 2 patients in the HGG group had aspergillus pneumonia, one of whom later died of chronic lung allograft dysfunction. Two patients had severe HGG (post-transplant IgG levels = 253 and 386 mg/dl, respectively); the former died of lethal severe pneumonia and the latter suffered severe pneumonia, later died of post-transplant lymphoproliferative disorder. All dead recipients were transplanted for BO after HSCT. The infection rates were 0.30 (95% confidence interval (CI): 0.016-0.58) in the NGG group and 0.47 (95% CI: 0.25-0.70) in the HGG group, and there was no significant difference between the groups (P = 0.37). The survival rates were 1.00 in the NGG group and 0.84 (95% CI: 0.68-1.01) in the HGG group without significant difference (P = 0.18; Table 3 ).
The infection rates in the non-severe HGG and severe HGG groups were 0.40 (95% CI: 0.21-0.59) and 0.50 (95% CI: 0.010-0.99), and there was no significant difference (P = 0.71). The survival rate in the non-severe HGG group was 0.96 (95% CI: 0.88-1.04) and that in the severe HGG group was 0.50 (95% CI: 0.010-0.99), and there was significant difference between the groups (P = 0.0050; Table 4 ).
DISCUSSION
In this study, we found that post-transplant Ig levels were generally significantly lower than pretransplant levels. Post-transplant IgA and IgG levels were significantly lower than pretransplant levels in patients with BO after HSCT, ILDs and BE, and pretransplant IgG levels were significantly lower in patients with BO after HSCT than in the others, although the post-transplant differences were not significant. Patients with HGG showed more infections than NGG patients and only the HGG group had CMV infection, aspergillus pneumonia and lethal pneumonia; however, no significant difference was found. Patients with severe HGG had a significantly lower survival rate than non-severe HGG patients. Among them, 2 patients transplanted for BO after HSCT had severe pneumonia and finally died, suggesting an association between Ig deficiency and poor prognosis, especially in BO after HSCT patients.
In the present study, the post-transplant HGG rate was 65.5% (19 of 29 patients) and severe HGG rate was 14% (4 of 29 patients), which were compatible with the findings of other reports indicating HGG prevalence between 44 and 73% [1, [7] [8] [9] . The prevalence of HGG was 70% for IgG levels <600 mg/dl [7] and 60% [8] and 73% [1] for IgG levels <700 mg/dl, while the rates of severe HGG (IgG < 400 mg/dl) were 37% [7] , 14% [8] and 15% [1] . HGG occurs commonly after solid organ transplantation, presumably as an effect of immunosuppressive therapy [10, 11] . MMF immunosuppression is more potent than azathioprine and inhibits both T-and B-cell proliferation [12] , and a randomized clinical trial comparing MMF with azathioprine after kidney transplantation showed clear MMF-related reductions in IgG levels [12] . Yip et al. [1] showed that predictors of post-transplant IgG levels included MMF use and pretransplant IgG levels. We did not directly assess the effect of MMF in the present study because we have used MMF for almost all recipients with noninfectious disease.
To our knowledge, there are currently no other reports regarding HGG in patients transplanted for lung diseases other than  COPD [1, 8, 9, 13, 14] . The present study analysed the trend of Ig levels in patients transplanted for BO after HSCT, ILDs and BE. BO after HSCT is a major indication for lung transplant in Japan. HSCT is associated with chronic, progressive and irreversible pulmonary disease, including BO and pulmonary fibrosis, and definitive medical therapies have not been established for these potentially fatal complications [15] . Debilitating post-HSCT BO has been reported in 2-26% of cases and is associated with mortality rates as high as 61% [16] . Although 85-90% of the patients show normal pretransplant Ig screening results [1, 7] , in the current study, pretransplant IgG levels in patients transplanted for BO after HSCT were significantly lower than those in patients with other underlying diseases. This might have resulted from conditioning regimens for allogeneic SCT and/or the immunosuppressive agents used post-HSCT to arrest pulmonary complications. Overall, the posttransplant IgG levels in BO after HSCT patients were not significantly different from those of the other patients, but most of the patients transplanted for BO after HSCT had HGG after lung transplantation. As 2 BO after HSCT patients with severe post-transplant HGG ultimately died with lethal infections, there may be the lower limit of HGG around 400 mg/dl and infection may occur more and severer beyond this threshold, as is stated previously [1, 8] . These findings emphasized the need for close monitoring.
ILDs and BE are also major indications for lung transplantation in Japan. Pretransplant IgA and IgG levels were significantly higher in patients transplanted for ILDs and BE in the present study than in patients with BO after HSCT, and post-transplant IgA and IgG levels in ILDs and BE patients were significantly lower than the pretransplant levels.
IgA is the major Ig in mucosal secretions, and only two studies so far have assessed serum IgA status in paediatric and adult lung transplantation [9, 17] . Robertson et al. [17] reported that low serum IgA levels were a significant risk factor for invasive aspergillosis in paediatric lung transplantation, and Chambers et al. [9] identified an independent effect of circulating IgA on the risk of communityacquired respiratory viral infections, suggesting a greater role of circulating IgA in mucosal defence than was previously understood. In our study, IgA levels in patients with BO after HSCT were significantly lower than in the others, but there were no evident correlations between low IgA levels and infectious complications.
Several authors have also reported the implications of HGG after kidney [5] , heart [11] and lung [7] [8] [9] transplantation while Goldfarb et al. [7] have described severe HGG in a group at extremely high risk of bacterial and fungal infections, tissue-invasive CMV and poorer survival after lung transplantation. Kawut et al. [8] reported that patients with severe HGG had a higher cumulative incidence of pneumonia and poorer survival, Chambers et al. [9] found the association of infectious complications, with not only invasive fungal infection, but BO syndrome, as chronic allograft lung dysfunction. The lowest IgG levels were recorded in Goldfarb's study [7] , and IgG levels at different and more distant times after transplant were assessed by Chambers et al. [9] . In our small study, data evaluated were from 3 months after transplant and almost uniform in the study population. Although we did not have statistical significant difference, our HGG group had more infections than the NGG group, and 2 patients with severe HGG had lethal pneumonia. Moreover, 2 patients in the HGG group had aspergillus pneumonia, suggesting that HGG patients should be monitored carefully for aspergillus infection. It has been reported elsewhere that invasive aspergillosis occurred exclusively with HGG and was most prominent in patients with low IgG levels.
It is expected that the use of IVIG therapy in solid organ transplantation will increase in relation to support for its efficacy in the [18, 19] , but there are no reports confirming similar efficacy of IVIG in lung transplantation [7] [8] [9] . Moreover, the considerable expense, possible risks and unproven benefits of IVIG indicate the need for further studies [8] .
Monitoring IgG levels has shown value in identifying patients at increased risk of complication [7] . In a recent minireview, Jordan et al. [20] reported that monthly IVIG replacement restored immune function. However, they also noted the need for evidenced data about the benefits of IVIG after solid organ transplant. In our institution, IVIG was used at the local clinician's discretion in 3 BO after HSCT patients, and while the number and timing of doses varied, all 3 patients showed favourable outcomes. The present study had limitations. The number of patients included was small, and consecutive patients could not be assessed because of lack of pre-and/or post-transplant Ig levels in some cases. There was a relatively larger number of LDLLT cases, in which the underlying diseases were quite different from those mentioned in previous reports. As LDLLT is an appropriate indication for urgent recipients with poor condition, there might be a possibility of selection bias. Moreover, our analyses were performed among disease subgroups including BO after HSCT, ILDs and BE. The absence of a significant association between HGG and infectious complications might have resulted from the relatively short follow-up period and our relatively successful infection control.
In conclusion, post-transplant Ig levels were significantly lower than pretransplant levels, and pre-and post-transplant IgA levels as well as pretransplant IgG levels were significantly lower in patients transplanted for BO after HSCT compared with those transplanted for ILDs and BE. Differences in post-transplant IgG levels were not significant. Nineteen of 29 patients had HGG after lung transplantation and had more infections than the NGG patients, although the difference between the groups was not significant. Ig levels in HGG patients should be monitored carefully because of the poor prognosis associated with severe HGG, especially in the patients transplanted for BO after HSCT. Further studies are needed to provide evidenced data about IVIG replacement therapy and infection control after lung transplant. In the future, we would like to plan a prospective multi-institutional study with a larger sample size or setting up an international registry.
